Examples of 'evaluated in patients' in a sentence
Meaning of "evaluated in patients"
This phrase is often used in medical or healthcare contexts. It means that a particular treatment, intervention, procedure, or medication has been assessed or examined in a group of individuals known as patients. The phrase indicates that the effects, outcomes, or benefits of the mentioned intervention have been studied and analyzed in a controlled setting involving patients
How to use "evaluated in patients" in a sentence
Basic
Advanced
evaluated in patients
Zavesca has not been evaluated in patients with hepatic impairment.
Concomitant use of lipegfilgrastim with any chemotherapeutic medicinal product has not been evaluated in patients.
Inotersen has not been evaluated in patients undergoing liver transplant.
Concomitant use of pegfilgrastim with any chemotherapy medicinal product has not been evaluated in patients.
Lapatinib has not been evaluated in patients with symptomatic cardiac failure.
Is use of Neupopeg with any chemotherapy agent has not been evaluated in patients.
Pravastatin has not been evaluated in patients with homozygous familial hypercholesterolaemia.
The pharmacokinetics of perampanel have not been formally evaluated in patients with renal impairment.
STELARA has not been evaluated in patients who have undergone allergy immunotherapy.
The safety and efficacy of Aldurazyme have not been evaluated in patients with a.
Umeclidinium has not been evaluated in patients with severe hepatic impairment.
Concomitant use of Neupopeg with any chemotherapy agent has not been evaluated in patients.
Pharmacokinetics were not evaluated in patients with increased severity of hepatic impairment.
Concomitant use of Ristempa with any chemotherapy agent has not been evaluated in patients.
The pharmacokinetics of aliskiren were evaluated in patients with varying degrees of renal insufficiency.
Concomitant use of Neulasta with any chemotherapy agent has not been evaluated in patients.
The pharmacokinetics of cabozantinib was not evaluated in patients with severe hepatic impairment.
Concomitant use of Pegfilgrastim Mundipharma with any chemotherapy agent has not been evaluated in patients.
The pharmacokinetics of clobazam were evaluated in patients with mild and moderate renal impairment.
Concomitant use of Pelgraz with any chemotherapeutic medicinal product has not been evaluated in patients.
The pharmacokinetics of ranolazine have been evaluated in patients with mild or moderate hepatic impairment.
First, the effect of diabetes on systemic metabolism was evaluated in patients.
The pharmacokinetics of aliskiren were evaluated in patients with end stage renal disease receiving haemodialysis.
Currently, the immunoglobulin E reactivity of the above ingredients is being evaluated in patients.
The pharmacokinetics of PegIntron have not been evaluated in patients with severe hepatic dysfunction.
Inotersen was not evaluated in patients undergoing liver transplantation in clinical trials ( section 4.2 ).
The pharmacokinetics of ViraferonPeg have not been evaluated in patients with severe hepatic dysfunction.
GLEEVEC ® is being evaluated in patients with pulmonary fibrosis.
Fluoxetine dosages exceeding 60 mg daily have not been evaluated in patients with bulimia.
The efficacy was not evaluated in patients without a confirmed NLRP3 gene mutation.
Thus, risk factors for heart disease must be evaluated in patients with diabetes.
The efficacy was not evaluated in patients without a confirmed NLRP3/CIAS1 gene mutation.
The pharmacokinetics of peginterferon beta-1a has not been evaluated in patients with hepatic insufficiency.
Silodosin has not been evaluated in patients less than 18 years of age.
Third, the long-term survival of a cyanotic CHD was retrospectively evaluated in patients with PA+VSD.
Binimetinib has not been evaluated in patients with Gilbert 's disease.
Pharmacological reduction in cortisol synthesis has also been evaluated in patients with type 2 diabetes.
Weaning indices have also been evaluated in patients on MV for prolonged periods.
Seizures, Ebixa ( memantine hydrochloride ) has not been systematically evaluated in patients with a seizure disorder.
Fosaprepitant has not been evaluated in patients below 18 years of age.
The pharmacokinetics of penciclovir have not been evaluated in patients with severe hepatic impairment.
Safety and efficacy has not been evaluated in patients with hepatic impairment see section 5.2.
The pharmacokinetics of CE / bazedoxifene have not been evaluated in patients with renal impairment.
Polivy has not been evaluated in patients with HIV.
The pharmacokinetics of eslicarbazepine has not been evaluated in patients with severe hepatic impairment.
The use of methadone has not been extensively evaluated in patients with renal insufficiency.
Therapeutic risks and benefits should be carefully evaluated in patients with active or suspected infections.
Hepatic impairment Miglustat has not been evaluated in patients with hepatic impairment.
The pharmacokinetics of Kyprolis has not been evaluated in patients with severe hepatic impairment.
The safety and efficacy of Neupopeg have not been evaluated in patients receiving chemotherapy o.
You'll also be interested in:
Examples of using Patients
Show more
Patients at the very heart of our mission
We have the best patients in the world
Patients also pay for essential drugs
Examples of using Evaluated
Show more
It should be evaluated over the coming year
Very few of these measures have been evaluated
Outcomes can be evaluated on best environmental performance
